# reload+after+2024-01-21 05:47:18.293195
address1§1405 Research Boulevard
address2§Suite 125
city§Rockville
state§MD
zip§20850
country§United States
phone§240 243 8000
website§https://www.senseibio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. Its Tumor Microenvironment Activated Biologics platform is designed to unleash the anti-tumor potential of T cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company's pipeline includes SNS-101, SNS-103, and SNS-102, monoclonal antibodies, which are in early development stages for the treatment of solid tumors. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
fullTimeEmployees§26
companyOfficers§[{'maxAge': 1, 'name': 'Mr. John K. Celebi M.B.A.', 'age': 51, 'title': 'President, CEO & Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 799692, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Erin  Colgan', 'age': 42, 'title': 'Chief Financial Officer', 'yearBorn': 1981, 'fiscalYear': 2022, 'totalPay': 558828, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Edward  Van der Horst Ph.D.', 'age': 50, 'title': 'Chief Scientific Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 444867, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Lora  Pike', 'title': 'Vice President of Investor Relations & Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher W. Gerry J.D.', 'title': 'General Counsel & Secretary', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Stephanie  Krebs M.B.A., M.S.', 'title': 'Chief Business Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§9
boardRisk§7
compensationRisk§9
shareHolderRightsRisk§10
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.02
currency§USD
dateShortInterest§1702598400
forwardEps§-1.08
exchange§NGM
quoteType§EQUITY
shortName§Sensei Biotherapeutics, Inc.
longName§Sensei Biotherapeutics, Inc.
firstTradeDateEpochUtc§1612449000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§0e733dd6-5a8f-3a8d-91c0-8d1a525a8226
gmtOffSetMilliseconds§-18000000
targetHighPrice§6.0
targetLowPrice§4.0
targetMeanPrice§4.67
targetMedianPrice§4.0
recommendationMean§1.3
recommendationKey§strong_buy
numberOfAnalystOpinions§3
quickRatio§11.566
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
